@__GhD_

God 1st. | STEM creative| Biochem/Molec Bio PhD | Dir. of Funding @VanguardSTEM | Equity Research @ Citizens/JMP tweets = my thoughts

Joined August 2020
  • Tweets794
  • Following92
  • Followers285
30Media
Hey friends, I’m Geraldine Ezeka #BlackInCancerRollCall. I’m a 5th year PhD candidate @UMmedschool identifying different molecular targets of sulforaphane, a nature derived anti-cancer agent, in mesothelioma.
2
19
2
154
Dr. Geraldine, PhD retweeted
VanguardSTEM@VanguardSTEM10 Feb 2025
5 Tips for Turning Your PhD Internship into a Full-Time Offer! medium.com/vanguardstem-conv…

5 Tips for Turning Your PhD Internship into a Full-Time Offer

Dr. Markaisa R. Black, a scientist at Procter & Gamble (P&G), shares how an impressionable internship experience can land a full-time…

medium.com
1
2
226
hey STEMverse: during your PhD (or research experience), did you find that 1 of the limitations to your progress was 1) inadequate reagents (ex antibodies that sucked) 2) inadequate equipment (ex equipment didn’t do as suggested) or 3) improper protocol 4) or a mix of the above?
52
Another twist... FDA permits use of Sarepta Therapeutics’ $SRPT Duchenne therapy in younger patients after short-lived halt statnews.com/2025/07/28/sare…

FDA permits use of Sarepta Therapeutics’ Duchenne therapy in younger patients after short-lived halt

The FDA said it was clearing the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular dystrophy to some patients. 

statnews.com
38
10
1
87
25,138
The $SRPT rollercoaster is not over. FDA recommended removal of voluntary hold on Elevidys for ambulatory patients and the $SRPT stock shot up ~50% after close, consistent with that trend, it’s up 40% at open.
1
57
$ABVX going from $10 to $69 after reporting positive Phase 3 data that no one believed in is insane. We were obvs bullish and anticipated a >100% increase upon positive data
40
Yesterday was a great day in neuropsychiatric drug development with GH Research reporting positive results from the Ph 2 trial evaluating their inhalation formulation of DMT for treatment resistant depression
2
1
102
Current standard of care JnJ’s SPRAVATO displayed a 4 point reduction in MADRS score while GH001 achieved a placebo adjusted 15 point reduction in MADRS
1
50
Yesterday GHRS stocks were up 85%. Excited to continue watching the story develop as we anticipate an update on the clinical hold, an end of Phase 2 meeting with the FDA, and their Ph3 design.
42
Sometimes good data isn’t all a company needs to be successful.
1
85
Let’s chat about Reviva Pharma Reviva Pharma is a clinical stage pharmaceutical company developing a serotonin/dopamine modulators in a host of indications with the lead being schizophrenia
112
A disheartening day for Alzheimer’s disease drug developers with disappointing results coming from both Cassava Sciences and Alector/Abbvie Phase 3 and Phase 2 clinical trials, respectively. Albeit the Cassava results were expected considering little impact seen in Phase 2
1
172
Cassava stocks plummet 85%…again, not a surprise considering the inconclusive Phase 2 results which begs the question, why did the FDA let them run a Phase 3?
49
I’m here to talk about science, biotech, biotech stocks (OUTSIDE OF MY COVERAGE) and banter.
47
Hi! @EthanInvests Thoughts on investing in psychedelic therapeutic companies?
1
1
148
Let’s go Amday!!!!
Amday Wolde, MD@AmdayMed25 Sep 2024
Hi #MedTwitter 👋🏾 My name is Amday Wolde! I’m an M4 at @OhioStateMed applying to #Psychiatry for #Match2025 I’m passionate about URiM mentorship (AmdayMed.com) & addressing SDOH! Academic interests are cultural & lifestyle psychiatry! My hobbies include ⚽️🏀👨🏾‍🍳
1
173
The neuro drug development space is one that experiences a bunch of difficulties 😭 /1
1
53
$MRNS developed an FDA approved oral ganaxalone, ZTALMY for a rare epileptic disease and expected expand into other developmental epileptic encephalopathies but failed to meet primary endpoints in the Phase 3 TSC trial. Upside? Company has a strong revenue asset to leverage.
101
Underperforming healthcare today…small/mid cap biotech gains seen during “Trump trade” (election last week) are all down. Inflationnnnnnn
1
42
Dr. Geraldine, PhD retweeted
VanguardSTEM@VanguardSTEM12 Nov 2024
Has your unique background influenced your perspective on STEM? We want to here from you! "At the Intersections" is our new series amplifying diverse voices in the field. Share your story! Submit a 150-word pitch to [email protected] for a chance to be featured!
1
1
130
Been working as a equity research associate for 2.5 months now, and boy have I learned SO much about the later stage biotech ecosystem
41
Load more